AVXX, formerly AveXis Inc., a biotechnology company focused on gene therapy, was acquired by Novartis in 2018 and is no longer actively traded. Due to its delisted status and lack of current financial reporting, comprehensive Shariah screening is limited by data insufficiency. All major Shariah indices exclude AVXX, leading to a non-compliant classification. Business activities in medical research appear permissible, but verification is impossible without updated disclosures. Investors should avoid or monitor for any residual holdings, with no purification required based on available data.